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ABSTRACT 
INVESTIGATION OF THE EFFECTS OF NICOTINE ON THE EXPRESSION 
PROFILE OF SW620 COLON ADENOCARCINOMA CELLS USING A 
FUNCTIONAL GENOMICS APPROACH 
 
Onur KAYA 
 
MSc. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Dr. Özlen KONU 
August 2009, 96 Pages 
 
Colon cancer is the third most common form of cancer with approximately 655,000 deaths 
worldwide annually and the second principal cause of cancer-related death in the Western world. 
Studies focusing on genomic instability and cell culture in recent years have shown that there is a 
statistically significant link between tobacco smoking and colorectal cancer. Although nicotine is 
one of the most potent chemical in tobacco, it was not studied extensively in colorectal cancers.  
Nicotine works as an agonist of nicotinic acetylcholine receptors and modulates the intracellular 
calcium concentrations hence deregulating multiple signal transduction pathways (e.g., 
PI3K/AKT, MAPK, mTOR).  It has been shown that nicotine accelerates cell proliferation while 
it increases cell migration, metastasis and angiogenesis, and inhibits apoptosis in lung and gastric 
cancers. The aim of this study was to give more insight into the association between nicotine and 
colon cancer by investigating the gene expression profiles of SW620 colon adenocarcinoma cells 
under 48h 1µM nicotine treatment at different serum levels to reflect molecular response to 
growth factor-induced and –depleted conditions (10% FBS or 0.1% FBS). We used multiple 
approaches including cell culture techniques, microarray technology, and gene-network analysis 
to assess the effects of nicotine on cell proliferation and transcriptome profile. Furthermore, the 
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selected genes that are involved in cell cycle and apoptosis were used to confirm and evaluate the 
transcriptome analysis results with real time qRT-PCR and Western Blot techniques. In this 
project, our findings indicated that serum starvation of SW620 colon adenocarcinoma cell line 
resulted in decreased cell proliferation, which could be rescued by 1µM nicotine via deregulation 
of multiple pathways including cell cycle, apoptosis, Ca
2+
 signaling, and ribosomal protein 
expression. This study implicated that nicotine-, thus acetylcholine-mediated signaling may have 
an important role in tumor development and metastasis. 
 
Key words: Nicotine, nicotinic acetylcholine receptors, SW620, colon cancer, microarray, serum 
starvation 
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ÖZET 
 
NİKOTİNİN SW620 KOLON ADENOKARSİNOM HÜCRELERİNİN GEN İFADE 
PROFİLİ ÜZERİNE OLAN ETKİSİNİN İŞLEVSEL GENOMİK YAKLAŞIMLARLA 
ARAŞIRILMASI 
 
Onur KAYA 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez Yöneticisi: Yard. Doç. Dr. Özlen KONU 
Ağustos 2009, 96 Sayfa 
 
Kolon kanseri her yıl dünyada 655.000’e yakın kişinin ölümüne sebep olmakta dünyada en 
üçüncü, Batı dünyasında ise kanserle ilgili ölümlere sebep olmakta ikinci sıra bulunan kanser 
tipidir. Son yıllarda genomik kararsızlıklarla ilgili yapılan çalışmalar sigara kullanmakla 
kolorektal kanser arasında istatistiksel olarak kayda değer bir ilişki olduğunu göstermiştir. 
Sigarada bulunan kimyasallar içinde nikotin, sigaranın etkisini belirlemede çok önemli bir yer 
teşkil etmesine rağmen, kolorektal kanser araştırmalarında çok fazla kullanılmamıştır. Nikotinik 
kolinerjik reseptörlerine agonist olarak bağlanan nikotin, hücre içi kalsiyum konsantrasyonu 
üzerine etki ederek bir çok sinyal yolağının (PI3K/ AKT, MAPK, mTOR yolakları gibi) 
düzensizleşmesine, aktif ya da inaktif olmasına neden olur. Nikotin üzerine yapılan çalışmalar 
göstermiştir ki, nikotin hücre çoğalmasını hızlandırmakla beraber hücre göçü, hücre metaztazı, 
ve anjiyogenez (damar gelişmesini) olaylarını da arttırmakta, ayrıca akciğer ve gastrik 
kanserlerde apoptozu engellemektedir. Bu çalışmamızda, SW620 kolon adenokarsinom 
hücrelerini farklı serum şartlarında, 48 saat boyunca 1µM nikotine maruz bırakarak nikotin-kolon 
kanseri ilişkisini aydınlatmayı amaçladık. Bu amacımız doğrultusunda, hücre kültürü teknikleri, 
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mikrodizin teknolojisi ve gen-ağ analizleri içeren yaklaşımlar kullanarak nikotinin hücre 
çoğalması ve gen ifadesi profiline olan etkisini araştırdık. Bunların yanında, apoptozda veya 
hücre döngüsünde görev alan ve mikrodizinde etkili bir biçimde ifade  olan genleri belirleyerek 
bu genleri nicel gerçek zamanlı polimeraz zincir reaksiyonu ve “Western blot” tekniklerinde 
kullanarak mikrodizin çalışmasının doğrulamasını yaptık. Bu çalışmada, serumdan mahrum 
bırakılan SW620 kolon adenokarsinom hücrelerinin çoğalmasında belirgin bir azalma olmasına 
rağmen, aynı serum şartlarında 1µM konsantrasyondaki nikotin sayesinde hücreler hücre 
döngüsü, apoptoz, kalsiyum iyonu ve ribosomal protein yolakları gibi çeşitli sinyal yolaklarının 
aktivitelerini değiştirerek çoğalma özelliklerini belirli bir derecede geri kazanmıştır. Bu çalışma 
göstermiştir ki nikotin tarafından, bundan hareketle asetilkolin tarafında düzenlenen hücre içi 
sinyaller tümor gelişimi ve metaztaz mekanizmalarında önemli bir etken teşkil etmektedir. 
 
Anahtar sözcükler: Nikotin, nikotinik asetilkolin reseptörleri, SW620, kolon kanseri, mikrodizin
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CHAPTER 1. INTRODUCTION 
1.1 Colon Cancer 
1.1.1 Colorectal Cancer 
Colorectal cancers consist of cancers of the digestive system, namely colon and rectal cancers; the 
former includes cancers of the lower part of the digestive system (larger intestine-colon) while 
rectal cancers are characterized as originating from the end part of colon (last 6 inches) (Figure 
1.1A) [1]. With approximately 655,000 deaths worldwide annually, it is the third most common 
form of cancer and the second principal cause of cancer-related death in the Western world [2]. 
About 112,000 people are diagnosed with colon cancer per year, and approximately 41,000 new 
cases of rectal cancer are diagnosed annually, according to the American Cancer Society [1]. 
According to the 2009 statistics, among these cases, nearly 50,000 people have died because of the 
colorectal cancer [3]. Most of the colon cancer cases begin as small-benign clumps of cells called 
adenomatous polyps (Figure 1.1B). Thereafter, some of these polyps progress to become colon 
cancers.  
A B  
Figure 1.1: Human colon physiology A) Illustration of normal colon physiology in human body. 
B) Imaging of colon polyps inside of the large intestine tissue [3]. 
 2 
1.1.2 Risk Factors 
Although exact causes of colorectal cancer are not well known, there are some predicted reasons 
that may trigger the formation of cancer according to National Cancer Institute. Heritability and 
age are among the main risk factors for colorectal cancers. More than 90% of people with 
colorectal cancer are diagnosed after age 50 as colorectal polyps increase after that age and the 
average age for the disease is 72 [3]. Although colorectal cancer is not contagious, familial history 
takes important role in development of cancer.  Close relatives of a person with a history of 
colorectal cancer are somewhat more likely to develop this disease [1]. Moreover, mutations in 
some key-genes increase the risk of colorectal cancer. For instance, “Hereditary Non-Polyposis 
Colon Cancer (HNPCC)” is the most common type of inherited colorectal cancer. It accounts for 
approximately 2% of all colorectal cancers [4]. Most people with an altered HNPCC gene develop 
cancer at an early age [3]. Recurrence is a common theme in colorectal cancers [5]. In addition, 
women with a history of ovary, uterus or breast cancer have higher risks to develop colorectal 
cancers [3, 6]. Long-term Ulcerative colitis and Crohn’s disease history and diets high in fat and 
low in calcium foliate may also increase the risk of colorectal cancer [7, 8]. Another very 
important risk factor for development of colorectal cancer is tobacco smoking. A person who 
smokes cigarettes may have increased risk of developing adenomatous polyps. According to Strate 
et al., women and men who smoked have increased risk of dying from the disease, more than 40% 
and 30% respectively, when compared with those who never smoked [9]. 
1.1.3. Early Detection, Diagnosis and Staging 
Weakness, fatigue, change in bowel habits, diarrhea or constipation, red or dark blood in stool, 
weight loss, gas, abdominal pain, cramps, or bloating are some of the symptoms of colorectal 
cancer. Some other diseases also mimic these symptoms such as ulcerative colitis, diverticulitis, 
and peptic ulcer disease [3]. Colorectal cancer may develop for many years before the symptoms, 
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which vary according to the place of the tumor in the intestine [2]. Therefore, early detection of 
colorectal cancer gives a very important chance for treatment and better prognosis. The National 
Cancer Policy Board of the Institute of Medicine predicted in 2003 that efforts for developing and 
applying additional colorectal cancer screening methods would result in a 29% decrease in 
colorectal cancer deaths in 20 years [10]. There are many screening methods to detect colorectal 
cancer formation such as digital rectal exam (DRE), fecal occult blood test (FOBT), endoscopy, 
sigmoidoscopy, and colonoscopy. A colonoscopy has the advantage that if polyps are found during 
the procedure they can be immediately removed and tissue can also be taken for biopsy [11, 12]. 
Colon cancer staging is an approximation of the quantity of diffusion of a particular cancer 
[13, 14]. It is performed for both diagnostic and research purposes, and in order to decide the best 
way for cure. The systems for staging colorectal cancers depend on the extent of local invasion, the 
degree of lymph node participation and whether there is outlying metastasis [14]. Staging of 
metastasis frequently include Abdominal Ultrasound, CT, PET scanning, and other imaging 
studies. The most common staging system is the TNM (for tumors/nodes/metastases) system, from 
the American Joint Committee on Cancer (AJCC). The TNM system assigns a number based 
on three classes: "T" represents the grade of invasion of the intestinal wall, "N" denotes the degree 
of lymphatic node participation, and "M" symbolizes the degree of metastasis. Stages I to IV 
progressively indicate a more advanced cancer and worse prognosis (Table 1.1) [15]. 
Table 1.1:  The stages of the colorectal cancer [15]. 
AJCC stage  TNM stage criteria for colorectal cancer 
Stage 0  Tis: Tumor confined to mucosa; cancer-in-situ 
Stage I  T1: Tumor invades submucosa 
Stage I  T2: Tumor invades muscularis propria 
Stage II-A  T3: Tumor invades subserosa or beyond (without other organs involved) 
Stage II-B  T4: Tumor invades adjacent organs or perforates the visceral peritoneum 
Stage III-A  N1: Metastasis to 1 to 3 regional lymph nodes. T1 or T2. 
Stage III-B  N1: Metastasis to 1 to 3 regional lymph nodes. T3 or T4. 
Stage III-C  N2: Metastasis to 4 or more regional lymph nodes. Any T. 
Stage IV  M1: Distant metastases present. Any T, any N. 
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1.1.4 SW620 Human Colorectal Adenocarcinoma Cells 
The SW620 is a metastatic colon cancer cell line, which was established from a lymph node of a 
51-year-old  Caucasian male (blood group A, Rh+) patient with an undifferentiated 
adenocarcinoma of the ascending colon [16]. It consists mainly of individual small spherical and 
bipolar cells lacking microvilli that are highly tumorigenic [17]. In this cell line, p53 is mutated 
(Arg  His substitution at codon 273) [18] while several oncogenes also are expressed (c-myc, K-
ras, H-ras, N-ras, Myb, sis and fos; www.atcc.org). Moreover, APC, which is key regulator in β-
catenin signaling pathway, is mutated in SW620 cells [19]. 
1.2 Nicotine 
1.2.1 Smoking and Cancer 
Smoking is one of the worldwide reasons for cancer–related death. Research demonstrates that 
69% of all lung cancers in women and 91% in men are related to smoking [20]. Moreover, 
smoking is also one of the major reasons for the oral cavity, larynx, esophagus and stomach 
cancers for both smoking males and females [21]. Cigarettes consist of more than 4000 diverse 
chemicals and of these chemicals more than 60 are identified as carcinogens according to the 
research of International Agency for Research on Cancer (IARC). These carcinogens in 
cigarette smoke react with DNA leading to DNA modifications and mutations and finally 
causing genetic alterations that might have a role in cancer [22]. Nicotine is one of the 
carcinogens in the tobacco smoke. Its absorption may arise through the oral cavity, skin, lung, 
urinary bladder, and gastrointestinal tract [22]. Dissimilarly to the stomach, nicotine is well 
absorbed in the small intestine due to the higher pH and a large surface area [23]. Nicotine is 
known as a highly addictive chemical in tobacco taking the main role in addiction that leads to 
ongoing consumption of tobacco products. On the other hand, nicotine has an important role in 
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therapeutic applications for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s 
disease [24, 25]. 
 
1.2.2 History of the Nicotine 
Nicotine is an active alkaloid named after the tobacco plant Nicotiana tabacum (Solanaceae) 
[22].The systematic International Union of Pure and Applied Chemistry (IUPAC) name is (S)-
3-(1- methyl-2-pyrrolidinyl) pyridine (Figure 1.2). Pure nicotine is a clear liquid and it has a 
characteristic odor, while the color changes into brown on exposure to air. Nicotine is soluble 
in water and can be mixed with an equal amount of water. However, it prefers organic solvents 
[22]. 
 
Figure 1.2: IUPAC name and chemical structure of nicotine; tobacco plants images (left); 
illustration for the correlation of smoking and lung cancer. The illustration modified from Catassi 
et. al., 2008 [22]. 
1.2.3 Nicotine Metabolism  
Absorption of nicotine throughout the cell membrane relies on the pH property. If the pH is acidic, 
nicotine is ionized and does not easily pass through membranes [23]. In the lungs, nicotine is 
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rapidly captivated by the systemic circulation. The active form of nicotine is a cation, which is 
very similar to acetylcholine. It has been demonstrated that nicotine might compete and/or 
interferes with acetylcholine, which is the major neurotransmitter of the brain [26]. The binding of 
nicotine opens the ionic channel in a very few milliseconds and opening of these channels leads to 
a brief depolarization (Na
+
 through the cell) [27].  Nicotine also activates the dopamine system 
within the brain. An expanded exposure of these receptors to nicotine decreases the effectiveness 
of dopamine by repressing the number of suitable receptors [27]. When nicotine concentration 
decreases in the brain, the receptors turn into active state from desensitized state. The re-activation 
of receptors increases neurotransmission to an unusual rate [28].  
Nicotine is chiefly metabolized in the liver as well as in the lungs and the kidneys into 
many different metabolites (Figure 1.3). Quantitatively, cotinine (70-80% of nicotine converted to 
cotinine) and nicotine N'-oxide (NNO) (4-7% of nicotine converted to NNO) are the most 
important and primary metabolites of nicotine. They are the products hepatic oxidation of nicotine 
via cytochrome P-450 [29]. Cotinine is further metabolized to a number of metabolites including 
3'-Hydroxycotinine (3HC), 3HC-glucuronide conjugate (3HC-Gluc), and cotinine N-oxide (CNO) 
[30]. Indeed, it appears that most of the reported urinary metabolites of nicotine are derived from 
cotinine [30]. NNO can also be reduced back to nicotine that will lead to recycling of nicotine in 
the body. Other than these metabolites of nicotine, about 3-5% of nicotine is converted to nicotine-
glucuronide (Nicotine-Gluc) and excreted in urine [29]. Nornicotine is also shown as a metabolite 
of nicotine in human.  It has been detected in smokers' urine and about 1% of nicotine is converted 
to nornicotine. 
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Figure 1.3: Illustration of nicotine metabolism and its primary metabolites in the human liver 
(www.pharmgkb.org).  
1.2.4 Nicotine and Apoptosis 
Nicotine has a very important role in deregulation of key and regulator genes in apoptosis 
events. It is shown by Mai et al. that 1μM nicotine may prevent cisplatin-induced apoptosis via 
phosphorylation of Bcl2 in human lung cancer cells [31]. Another similar study performed with 
oral cancer cells has shown parallel results [32]. Banerjee et al. also have shown that nicotine 
inhibits apoptosis triggered by nitric oxide induction in oral epithelial cells and they have 
proposed that inhibition of apoptosis may lead tobacco- induced oral cancer formation [33]. 
Nicotine may also deregulate apoptotic pathways via inducing phosphorylation of Bax through 
activation of AKT [34]. Besides Bax phosphorylation, it is shown that phosphorylation of Bad 
may inactivate its pro-apoptotic activity via 1μM nicotine exposure in A549 lung cancer cells 
thus increasing cell survival [35, 36]. NF-κB signaling pathway and nicotine may also have 
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important associations in terms of apoptosis inactivation. Zhang et al. has shown that nicotine 
prevents menadion-induced apoptosis in A549 lung cancer cells via activation of NF-κB [37]. 
Nicotine also suppresses opioid-induced apoptosis in human lung cancer cells [38]. According 
to another study nicotine alleviates oxidative stress, activates NF-kB and sensitizes cells to 
genotoxic/ xenobiotic stresses in HCT116 colon cancer cell line [39]. Furthermore, nicotine 
prevents apoptosis triggered by some apoptotic drugs like taxol and gemcitabin via increasing 
gene expression of apoptosis inhibitor XIAP (i.e. BIRC4) and Survivin (i.e. BIRC5) genes in 
non-small cell lung cancer (NSCLC) in a dose and time dependent manner [40]. Nicotine also 
weakens and decreases apoptosis rate triggered by serum starvation [41]. Besides these 
findings, nicotine unfavorably affects the cytotoxicity of DNA-damaging agents like cisplatin, 
UV, and gamma radiation in head and neck cancer cells. According to studies of Onoda et al. 
in these cells, nicotine does not affect the DNA damage repair mechanism but directly 
interferes with the signaling of the death pathway, reducing the signaling of the JNK1 pathway 
[42].  
1.2.5 Nicotine and Cell Proliferation  
Nicotine has an effective role in stimulation of cell proliferation and growth via many diverse 
mechanisms and signaling pathways. In one study, Ye et al. have shown that nicotine promotes 
cell proliferation in SW1116 colon cancer cell lines via phosphorylation of (epidermal growth 
factor receptor) EGFR and c-Src followed by an increased in 5-LOX (lipoxygenase) expression 
[43]. Besides, nicotine suppresses the growth inhibitory effects of trans-retinoic acid (RA) by 
inhibiting RA receptor-β (RARβ) expression throughout its induction of TR3 expression in 
lung cancer cells according to the results of Chen et al [44]. Shin et al. has also shown the 
promoting activity of nicotine on gastric cancer cell proliferation and vascularization through 
sequential gene activation of ERK/COX-2/VEGF signaling pathway [45]. Another interesting 
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study was performed with mouse epithelial cells. Long-term exposure of these cells to nicotine 
disorders cell cycle restriction machinery and cell cycle check points via targeting Ras pathway 
and induces Cyclin D1 [46]. Nicotine has also a role in AKT pathway. Nicotine and NNK 
activates Akt via α3/α4 or α7 nAChRs thus lessens etoposite-, UV- or H2O2- induced apoptosis 
through phosphorylation of GSK-3β, p70S6K, 4EBP-1, and FKHR [47]. Nicotine increases the 
proliferation of human small cell lung carcinoma SHP77 cells, indirectly increasing the 
expression levels of bombesin-like peptides [48]. Nicotine and its nitrosated carcinogenic 
derivative NNK actively bind to α7-nicotinic acetylcholine receptor (nAChRα7), and this 
activates MAPK through PKC/Raf-1, leading to the cell proliferation and finally development 
of lung cancer [49]. Nicotine also promotes gastric cancer via cyclooxygenase-2 (COX-2) /c-
myc/ODC sequential activation [50]. Besides these, nicotine persuades cell proliferation of 
pancreatic cancer cell line AR42J via activating p-ERK1/2 in independent manner of its 
secretory response [51]. Also, rapid activation of ERK1/2 and Stat-3 by nicotine stimulates cell 
proliferation in bladder cancer [52]. Moreover, nicotine increases Rb-Raf1 complexes in 
human lung cancer cells lines via interaction with β-arrestin via nAChR α7 and depends on Src 
activity [53]. In one of the recent studies of Wong et al., it has been shown that β-adrenergic 
activation plays a regulatory role in the proliferation of colon cancer via promotion of nicotine 
[54]. They also imply that nicotine stimulates cell proliferation via nAChRα7 in human colon 
adenocarcinoma HT-29 cells [55]. Another recent study suggests that nicotine increases 
proliferation of lung cancer cells through induction of fibronectin and α5β1 integrins and these 
events refereed by nAChR-mediated signals that consist of ERK and PI3-K/mTOR pathways 
[56]. 
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1.2.6 Nicotine and Microarray Studies 
Saito et al. have shown that multiple MAPK signaling components, GABA receptors and 
protein phosphatases have been involved in nicotine-induced changes in brain [57].  Konu et al, 
have suggested that the genes belong to PKC, MAPK, NF-κB and ubiquitin/ proteasome 
signaling pathways are affected by nicotine via their microarray studies in rat brains [58].  
Konu et al. also suggest via microarray studies with PC12 cells (derived from a 
pheochromocytoma of the rat adrenal medulla) that nicotine might lead to regulation of 
ribosomal and proteosomal protein subunits, many growth factors, and heat-shock proteins 
[59].  It is also worth noting that although there are such microarray studies performed with 
nicotine in neuronal cells, no microarray study exists for understanding the effects of nicotine 
on colon cancer cells. 
1.3 Nicotinic Acetylcholine Receptors 
1.3.1 General Information 
Nicotinic acetylcholine receptors, also known as nAChRs or CHRNs, are cholinergic receptors that 
form ionotropic (i.e. ligand-gated) ion channels in the plasma membranes of definite neuronal cells. 
nAChRs are directly associated to an ion channel and do not activate a secondary messenger as 
some other receptor types [60]. nAChRs take their names from nicotine, agonist of cholinergic 
receptors as they can also be triggered by nicotine besides acetylcholine ligand [61]. Although 
nAChRs are mainly found in the central nervous system and the peripheral nervous system [60], 
current research show the expression of nAChRs in non-neuronal tissues [62].  
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1.3.2 Structure of nAChRs 
nAChRs, with a molecular mass of 290 kDa, form hetero-pentamers on the cell surface and they 
settle symmetrically around a central pore [60, 61, 63] (Figure 1.4). These receptors are clustered 
into two subtypes (muscle and neuronal type) according to their primary sites of expression. The 
muscle types are found in neuromuscular connections and they are either the embryonic form, 
composed of α1, β1, δ, and γ subunits in a 2:1:1:1 ratio, or the adult form composed of α1, β1, δ, 
and ε subunits in a 2:1:1:1 ratio [60, 61, 64]. The neuronal subtypes have diverse homomeric or 
heteromeric pentamers combinations of twelve different nicotinic receptor subunits: α2 -α10 and 
β2 -β4 like (α4)3(β2)2 [60]. In both of the subtypes, the subunits are similar to each other in terms 
of hydrophobic regions. The neuronal subunits differ from the muscle ones in one way they are not 
responsive to α-bungarotoxin [60].  
 
Figure 1.4: The structure of the nAChR receptor/channel. (A) Each receptor subunit crosses the 
membrane four times. The membrane-spanning domain that shapes the pore is shown in blue. (B) 
Five such subunits come together to create a pentamer structure containing twenty trans-membrane 
domains that surround a central pore. (C) The openings at either end of the channel are very large -
ca. 3 nm in diameter; yet the narrowest area of the pore is approximately 0.6 nm in diameter (in 
comparison, the diameter of Na
+
 or K
+
 is less than 0.3 nm.) [60]. 
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1.3.3 Function of nAChRs 
1.3.3.1 General Functions of Nicotinic Acetylcholine Receptors 
The existence of the loops on the extracellular regions of nAChRs preserves the binding site for 
the neuro-transmitter acetylcholine (ACh) which is the physiologically agonist of all nAChRs 
subunits [65, 66]. Long-exposure to acetylcholine might lead to stabilization of the receptor 
causing desensitization of the receptor [67, 68]. Aside from the agonistic or antagonistic binding 
site, diverse interaction sites are present on nAChRs for both non-competitive inhibitors and 
allosteric modulators [69].  
1.3.3.2 Nicotine and Nicotinic Acetylcholine Receptors 
Similar to ACh interactions with the receptor complex, nicotine binds as an agonist to the α 
subunits of nAChRs [70] (Figure 1.5). Nicotine interacts with nAChRα4β2 in higher affinity than 
it does with the nAChRα7 [71]. Interestingly, chronic nicotine exposure causes desensitization of 
nAChRα4β2, but not of nAChRα7 [72]. Desensitization is short-lived and removal of nicotine 
exposure re-establishes receptor affinity [73].  
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Figure 1.5: Nicotine and acetylcholine interaction with nAChRs. A) Depiction of nicotine and 
acetylcholine interaction with nicotinic receptor subunits (nAChR). B) Schematic representation of 
nAChRs structure [22]. 
Nicotine-receptor interaction guides a conformational change in the receptor and releases 
the gate on the intracellular side of the ion channel in the plasma membrane. Ion influx into the cell 
causes membrane depolarization [74, 75]. Following this initial depolarization voltage-activated 
Ca
2+
 channels gates open, resulting in an extra Ca
2+
 influx to the cells, which in turn leading to 
deregulation of Ca
2+
 activated signaling cascades , and release of neurotransmitters. Accordingly, 
activation of nACHRs might have a very critical role in cell division, self-renewal, differentiation, 
proliferation, senescence, apoptosis, and migration [76, 77].   
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CHAPTER 2. OBJECTIVES AND RATIONALE 
 
Colon cancer is one of the leading causes of death in the world and early diagnosis provides 
better treatment opportunities. Nicotine, an addictive and modulatory molecule in tobacco has 
been associated with lung cancer initiation and progress yet the impact of nicotine-driven 
signaling on colorectal cancer cells have not been studied in detail and/or at the transcriptional 
profile level. Furthermore, it is apparent that serum levels in cell culture systems reflect 
changes in growth factors, and serum starvation models help us understand the cellular 
proliferation and apoptosis mechanisms in cancer cells. Previous studies are focused on 
nicotine’s effects in systems with serum ad libitum, however, there is indications that serum 
levels modify nicotine’s effects [46]. Moreover recent studies have shown that nicotine has a 
critical role in cell cycle proliferation, in apoptosis and cell invasion, yet mostly in lung cancers 
[40, 53, 78]. But there is no microarray study, which may help understanding the nicotinic 
signaling pathways in cancer cells of colon. Therefore, the aim of this study is to understand 
serum-dependent and –independent as well as dose- and time-specific actions of nicotine on 
colon cancer using molecular and biochemical methods as well as whole genome transcriptome 
profiling.  
The following questions were asked in this study: 
1) At what dose and time period does nicotine show its effect for cell proliferation? This 
question was addressed primarily by using MTT cell viability assay. 
2) Do proliferative or apoptotic effects of nicotine differ with respect to levels of serum in cell 
growth media? This question was addressed by the following approaches a) MTT assays 
for cell proliferation b) Determination of cell cycle and apoptotic genes expression at 
protein levels c) Comparing the expression profiles of the nicotine treated cells with or 
without serum. 
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3) What cellular signaling pathways are involved in nicotine’s serum-dependent effects? This 
question was addressed by using gene lists obtained by gene set-enrichment analysis and 
network visualization methods. 
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CHAPTER 3. MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 General chemicals 
All laboratory chemicals were supplied by Sigma-Aldrich (St. Louis, MO, U.S.A), Farmitalia 
Carlo Erba (Milano, Italy) and Merck (Schucdarf, Germany), except Ethanol and methanol were 
from Riedel-de Haën (Germany). Agarose was obtained from Gibco (Carlsbad, CA, USA).  
3.1.2 RNA Isolation, PCR and cDNA synthesis kits 
The RNA isolation was performed using Promega RNA isolation kit, (Madison, USA; Z3100). 
RevertAid first strand cDNA synthesis kit (MBI Fermentas) and qRT-PCR kit, SYBR-Green 
(Finnzymes), were used to obtain cDNA and to amplify cDNA, respectively. 
3.1.3 Oligonucleotides: The oligonucleotides used in quantitative Reverse Transcriptase-
polymerase chain reaction (qRT-PCR) were obtained from Iontek Inc. (Istanbul, Turkey). The 
oligo sequences of the primers were shown on Table 3.1. 
Table 3.1: The sequences of primers used for microarray verification experiment via qRT-PCR (F: 
Forward primer, R: Reverse primer) 
Primer ID  Sequence (5’   3’) Product Length (bp) Temperature(oC) 
XIAP (F): TCACTTGAGGTTCTGGTTGC 113 60 
XIAP (R) CGCCTTAGCTGCTCTTCAGT   
SURVIVIN (F) GTTGCGCTTTCCTTTCTGTC 141 60 
SURVIVIN (R) TCTCCGCAGTTTCCTCAAAT   
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3.1.4 Western Blotting materials 
3.1.4.1 Kits and reagents: ECL plus western blotting reagent was supplied from Amersham (UK; 
RPN2132) and SuperSignal West Femto reagents was obtained from Perbio Perbio (UK; 34095). 
Protein size marker was obtained from MBI Fermantas (PageRuler Prestained, Cat No: SM0671).  
3.1.4.2 Antibodies: Calnexin primary antibody (CL731, Sigma) and anti-mouse HRP conjugated 
secondary antibody (A0168, Sigma) were kindly provided by Mehmet Ozturk group. Pro-apoptotic 
gene Bax primary antibody (SC-529, Santa Cruz) and cell-cycle protein antibody (Cyclin E (SC-
481, Santa Cruz) were kindly provided by K. Can Akcali Group. Anti-rabbit HRP conjugated 
secondary antibody was obtained from Santa Cruz (USA). The primary antibodies were diluted 
into 1:200 to 1:5000 concentrations, while the secondary antibodies were diluted in blocking 
solution (1:5000, as recommended by the supplier).   
3.1.4.3 Protein transfer materials: Immobilen P transfer (PVDF; Roche; Germany), and 3mm 
Whatman filter paper (Whatman International Ltd.; Madison, USA) were used for protein transfer. 
3.1.5 Electrophoresis, photography, spectrophotometer and autoradiography: The films 
(KODAK; Rochester, USA) were developed using Hyperprocessor (Amsderdam, UK). The power 
supply Power-PAC300 and Power-PAC200 were from Bio Rad Laboratories (CA, USA). 
Beckman Spectrophotometer Du640 (CA, USA) and Nanodrop ND-1000 Full-spectrum UV/Vis 
Spectrophotometer purchased from Thermo Fisher Scientific (Wilmington, DE, USA) were used 
for protein visualization, gel electrophoresis and nucleic acid measurements, respectively. 
3.1.6 Tissue culture reagents and cell lines: Dulbecco’s modified Eagle’s Medium (DMEM), and 
trypsin were obtained from Biochrom (UK); fetal bovine serum and penicillin/streptomycin were 
supplied from HyClone (Logan, USA). SW620 Colon Adenocarcinoma cells (ATCC; CCL-227) 
were kindly provided by Assist. Prof. Dr. Sreeparna Banerjee, METU. 
3.1.7 Microarrays: HG-U133 plus 2 microarray chips and reagents were supplied from 
Affymetrix (USA). 
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3.1.8 Nicotine: Liquid nicotine was supplied from Sigma (USA; 54-11-5).  
3.1.9 Cell proliferation experiment kits and reagents: Vybrant MTT cell proliferation kit was 
obtained from Invitrogen (V13154, USA). 
3.2 SOLUTIONS and MEDIA 
3.2.1 General solutions 
50X Tris-acetic acid-EDTA (TAE): 2 M Tris-acetate, 50 mM EDTA pH 8.5. Diluted to 1X for 
working solution. 
10X PBS: 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4 and 2.4 g KH2PO4 were dissolved in 800 ml 
dH2O and adjusted the pH 7.4 with HCl. ddH2O was added to complete the final volume 1 liter.  
2 M NaCl: 58.44 gr NaCl in 500 ml ddH2O  
10% SDS: 100gr SDS was dissolved n 900 ml ddH2O and heated to 68 0C to assist dissolution. 
Then, pH was adjusted to 7.2 and final volume was completed to 1lt by adding ddH2O.  
3.2.2 Cell culture solutions: 
Complete media: DMEM was supplemented with 10% fetal bovine serum and 1% penicillin 
/streptomycin mixture and stored at 4
o
C. 
Serum starvation media: DMEM was supplemented with 0.1% fetal bovine serum, 1% penicillin 
/streptomycin mixture and stored at 4
o
C. 
Cell freezing solution: 5% DMSO and 95% complete media were mixed. 
1XPBS: 10X PBS was diluted to 1X PBS solution with dd-water and adjusted pH at 7.4. Then, it 
was autoclaved and filtered before use.  
Media with nicotine: 2 μl Nicotine was dissolved in 1248 μl serum starved tissue culture medium 
to make 10mM Nicotine stock solution, prepared freshly. 100nM, 1μM, and 10 μM nicotine 
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solutions were prepared via serial dilution from 10mM Nicotine stock solution. All work was 
performed in dark and in a fume cupboard. 
3.2.3 SDS (Sodium Deodecyl Sulfate)-PAGE (Polyacrylamide Gel Electrophoresis) solutions: 
30% Acrylamide mix (1:29): Per 100 ml: 29 g acrylamide, 1 g bisacrylamide in double-distilled 
water, filtered, degassed, and stored at 4°C (stock solution). 5X SDS gel-loading buffer 3.8 ml 
double-distilled water, 1 ml of 0.5 M Tris-HCl, 0.8 ml glycerol, 1.6 ml of 10% SDS, 0.4 ml of 
0.05% bromophenol-blue. Before use, ß-mercaptoethanol was freshly added to a final 
concentration of 5% to reach 1% when mixed with protein samples. 
10% Ammonium persulfate (APS): 0.1 g/ml solution in double distilled water (Prepared freshly). 
1.5 M Tris-HCl, pH 8.8: 54.45 g Tris base (18.15 g/100 ml) ~150 ml distilled water. Adjust to pH 
8.8 with 1 N HCl. Completed to 300 ml with distilled water and stored at 4° C.  
1 M Tris-HCl, pH 6.8: 12.14 g Tris base ~ 60 ml distilled water. Adjust to pH 6.8 with 1 N HCl. 
Completed to 100 ml with distilled water and store at 4° C. 
3.2.4 Western-blotting solutions: 
Semi-dry transfer buffer per liter: 2.5 gr Glycine, 5.8 gr Tris base, 3.7 ml 10% SDS, 200 ml 
MeOH were dissolved in ddH2O to a final volume of 1 lt. 
10X Tris-buffer saline (TBS) Per liter: 100 mM Tris-base, 1.5 M NaCl, pH 7.6 in double 
distilled water. 
TBS-Tween (TBS-T): 0.5% Tween-20 solution in TBS. (Prepared freshly) 
Blocking solution: 5% (w/v) non-fat milk, 0.5% Tween-20 in TBS. (Prepared freshly). 
NP40 lysis buffer: 150 mM NaCl, 50 mM Tris.Cl at pH 8.0, 1% NP40 and 1X protease inhibitor 
mix wered mixed in dd H2O. 
Bradford working solution: 10 mg Coomassie brilliant blue was dissolved in 5 ml 95% ethanol 
and 10 ml 85% phosphoric acid completed to a final volume of 1 lt. with ddH2O. Then, the 
solutions were filtered by using whatman paper and stored at +4 
o
C in dark.  
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2X protein loading buffer: 50 Mm Tris. HCl at pH 6.8, 2 Mm EDTA at pH 6.8, 1% SDS, 10% 
glycerol and 0.02% Bromophenol blue solutions.  
5X Running Buffer: 15 gr Tris.base, 72 gr Glycine and 5 gr SDS were dissolved in ddH2O to a 
final volume of 1 lt. 
Resolving Gel Solution: 12% polyacrylamide gel (15 ml) was prepared:  
4.9 ml of dH2O, 6.0 ml of 30% Acrylamide mix, 3.8 ml of 1.5 M Tris, pH=8.8, 150 μl of 10% SDS, 
150 μl of 10% APS, and 6 μl of  TEMED. 
Stacking Gel Solution: 5% polyacrylamide gel (8 ml) was prepared:  
5.5ml of dH20, 1.3 ml of 30% Acrylamide mix, 1 ml of 1.0 M Tris, pH=6.8, 80 μl of 10% SDS, 80 
μl of 10% APS, and 8 ml of TEMED. 
3.3 METHODS 
3.3.1 Cell culture techniques:  
3.3.1.1 Cell lines: SW620 Colon Adenocarcinoma cell line (ATCC; CCL-227) is a lymph node 
derived metastatic colon adenocarcinoma. They were originally isolated from the tissue of a 51-
year-old Caucasian male (blood group A, Rh+) (www.lgcstandards-atcc.org). They are epithelial 
cells and strongly adherent to the plate. 
3.3.1.2 Growth conditions of the cell lines: SW620 cells were grown up in DMEM supplemented 
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin mixture. The cells were 
incubated in the 37
o
C incubator with 5% CO2. The cells were seeded to new flasks (or plates) in 
1:3- 1:5 ratio, every 2-4 days before reaching 90% confluence. The complete media were aspirated 
and cells were washed with 1X PBS for two times. Trypsin/EDTA solution was added to the flask 
to force cells to detach from the surfaces. The cells were dispersed by pipetting with the fresh 
media. Then, the cells were transferred to new flasks after counting with a hematocytometer. One 
day later, the media were replaced with fresh media.  Media and 1X PBS were kept at +4
o
C, 
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trypsin/EDTA was kept at -20
o
C. All cell culture solutions were heated to 37
o
C and equipment was 
cleaned with 70% ethanol before use. 
3.3.1.3 Cryopreservation of cell lines: Cells were harvested by using trypsin/EDTA and 
neutralized by adding fresh growth medium. The cells were precipitated by centrifuge at 1200 rpm 
for 3 minutes. The media/trypsin mixture was aspirated and the cells were resuspended in freezing 
media containing 5% DMSO in complete medium; resuspended cells in the freezing media were 
transferred into cryotubes; stored at -80
o
C overnight and then transferred to the liquid nitrogen 
tank for long-term storage.  
3.3.1.4 Thawing of the frozen cell lines: The cells were thawed rapidly at 37
o
C and mixed with 3 
ml complete growth medium; centrifuged at 1200 rpm for 3 minutes and precipitated. After 
removal of supernatant via aspiration, the cells were resuspended with fresh growth medium and 
transferred in 75-t flasks to 37
o
C. 
3.3.2 Nicotine treatment of the cells 
3.3.2.1 Time and dose-dependent nicotine treatments: Cells were harvested as described in 
section 3.3.1.2. Harvested cells were counted under the light microscope with hematocytometers. 
For 48 hours treatment, 10,000 cells/ well; for 72 hours 5000 cells/well; for 5 and 7 days 3000 
cells/well; for 15 days 1000 cells/well were seeded into the 96 well-plates. The cells were 
incubated for 24 h to attach the surface of the plate. After 24 h, the medium was replaced with the 
starvation medium to induce quiescence. After 24 h quiescence, the cells were treated with 
different levels of serum with or without different nicotine concentrations (cells Seeded  24h  
0.1% FBS treatment for quiescence  24h  cells treated with different conditions for 48h or 7 
days). To determine the optimum dose, a nicotine dose curve was applied using 100ηM, 1μM and 
10μM concentrations of freshly prepared nicotine (in the media). Nicotine concentrations were 
prepared in 10% FBS containing complete media or 0.1% FBS containing serum-deprived media. 
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After obtaining the quiescent cells, freshly prepared nicotine including media was applied to the 
cells for 48 and 72 hours experiments. For 5, 7 and 15 days experiments; first cells were incubated 
in the nicotine media for 3 days and then the media were changed with freshly prepared media 
with nicotine. The media were changed in between every 3 days. 
3.3.2.2 Nicotine treatment to the cells for RNA and protein extraction: The exponentially 
growing cells were harvested and counted. 1x 10
6
 cells were seeded to the 75 cm
2
 flasks in 
complete media and were incubated for 24 h for attachment to the plate. 24 hours later, complete 
media was replaced with the 0.1% FBS containing media for inducing quiescence. After another 
24h, the media was replaced with the nicotine containing media (four conditions: complete media-
control, 1 μM nicotine in complete media, 0.1% FBS media, and 1μM nicotine in 0.1% FBS 
containing media) and cells were incubated in the treatment medium for 48 h. Then, the cells were 
harvested via scrapper in the ice-cold 1X PBS. Later, cells were centrifuged at 1200 rpm for 3 min 
at 4 
o
C and the cell pellets were subjected to liquid nitrogen for snap-frozen. Then the pellets were 
stored at -80
o
C for further steps. Each condition had three biological replicas. The protein assays 
were performed only for two biological replicas. 
3.3.3 MTT cell viability assay: Vybrant MTT cell proliferation kit was used to see the cell 
proliferation rates of SW620 cells under different nicotine concentration and the results were 
obtained by ELISA reader. Firstly, MTT-powder was suspended in ice-cold 1 ml of 1X PBS and 
solution was kept in the dark. Later, the media including nicotine (or control media) were removed. 
100 μl of medium without serum was added to cells in each well and two wells were kept for 
empty (for blank reading). Next, 10 μl of MTT solution was added to the each well. The cells were 
incubated for 4 h at 37
o
C. Then, the media with MTT solution was removed and 100 μl ice-cold 
DMSO was added to the wells and mixed by pipetting. After 10 min incubation, the plates were 
read in Elisa-reader at 540 nm wavelength, with 450 nm reference wavelength. During analysis, 
blank wells were used for background reading and calculation. In MTT cell proliferation assay, the 
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significance of each condition’s effect was compared with the control using ANOVA followed by 
Fisher’s multiple comparison tests. 
3.3.4 Microarray analyses:  
3.3.4.1 Obtaining raw data: Four different conditions (Complete media control (1 replicate), 
1μM nicotine-treated complete media (1 replicate), 0.1% FBS containing media control (2 
replicates, and 1μM nicotine-treated 0.1% FBS containing media (2 replicates) were used for 
microarray experiments. The samples were prepared and hybridized on Affymetrix U133 plus 2 
GeneChips. 5μg RNA sample was used for each experiment (amplification/labeling/hybridization). 
Amplification, labeling and hybridizations were performed at the Genomics Core Facility of 
Bilkent University by the facility technician under the supervision Assoc. Prof. Dr. Işık Yuluğ 
according to manufacturer’s protocols. Affymetrix analysis software GCOS was used to perform 
the preliminary probe-level quantification of the microarray data. 
3.3.4.2 Data normalization: The data were further normalized using the justRMA 
normalization method by using the BrbArray Tools, 3.7 Version (http://linus.nci.nih.gov/BRB-
ArrayTools.html). The default option of RMA (with background correction, quantile 
normalization, and log transformation) was used to generate the normalized intensity for each 
probeset. The quality of microarray sets were tested via BRBArray Tools, Affy Data Quality 
Control utility (Figure 4.3).  
3.3.4.3 Determination of differentially expressed genes: Identification of differentially 
expressed genes was determined by BRB-Array-Tools using Class Comparison utility. The 
Geneset enrichment analysis with KEGG option (BrbArrayTools > Class Comparison > Between 
Group of Arrays) was performed with a threshold p-value <= 0.05. The differentially expressed 
genes were selected for the following conditions: Effects of nicotine on SW620 cells grown in 
0.1% FBS supplemented media in the presence or absence of nicotine. Effects of serum starvation 
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on SW620 cells was identified by subtracting 0.1% FBS treated cell expression profile from 10% 
FBS-treated cell expression profile (single replicate fold change).  
3.3.4.4 Gene Ontology (GO) analyses: After determination of the differentially expressed genes, 
the GO ontology analysis was performed in order to see the effect of nicotine on the biological 
functions and determine which biological functions were altered via nicotine and what kind of 
genes were differentially expressed under nicotine exposure conditions. To perform the GO 
ontology analysis, Webgstalt (WEB-based GEne SeT AnaLysis Toolkit) were used 
(bioinfo.vanderbilt.edu/webgestalt). When performing the gene ontology analyses, hyper-
geometric test were used with a p-value<0.05 and two genes were selected as a minimum number 
of genes. Level 4 and 5 were chosen for the biological level and molecular functions’ graphics. If 
the groups were significant according to selected criteria, the functions were written in red color. 
The graphs are shown in the Appendix A.  
3.3.4.5 Cluster analysis: Cluster 3.0 software together with Java TreeView software were used to 
hierarchically cluster the targeted genes according to different conditions of our microarray 
analyses. Upon median gene centering average linkage method of hierarchical clustering process 
was performed. During this process, both gene and array clustering were done, uncentered 
correlation was calculated to find the similarity.  
3.3.4.6 Pathway Miner analysis: It is important to observe the interactions between genes and/or 
proteins to understand the biological system in a holistic manner. Pathway Miner is one of the 
freeware programs that allow for visualization of genes that have roles in the same pathway thus 
each node represents a gene and each edge represents a co-occurrence within a cellular signaling or 
metabolic pathway (http://www.biorag.org). Differentially expressed gene lists obtained from 
different comparisons were filtered based on fold-change and consistency between experiments 
criteria and visualized using Pathway Miner. 
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3.3.5 Microarray Verification- RNA experiments 
3.3.5.1 Total RNA isolation: Total RNA isolation was performed directly by using Promega SV 
Total RNA isolation kit according to the manufacturer’s instructions. The RNA was eluted in a 
total volume of 50 μl RNAse free-H2O. The concentration of the isolated RNA and the ratio of 
absorbance at 260 nm/280 nm were measured with the Nanodrop ND-1000 spectrophotometer. 
Isolated RNA samples were stored at -80
o
C. For microarray analyses, 5μg/8μl concentration of 
RNAs were prepared. The integrity of isolated RNA samples for microarray chips was measured 
with the Agilent 2100 Bioanalyzer (Agilent Technologies, USA). The RNA integrity number 
(RIN) values and RNA concentrations were shown on Table 4.1.  
3.3.5.2 cDNA synthesis: For qRT-PCR experiments 2μg RNA used to get cDNAs. RevertAid first 
strand cDNA synthesis kit was used for cDNA production according to the manufacturer’s 
instructions. 
3.3.5.3 Quantitative real time RT-PCR experiments:  For qRT-PCR mastermix, 10μl SYBR-
Green qRT-PCR kit, 8 μl dd-H2O, 0.5 μl 20 pmol forward primer, 0.5 μl 20 pmol reverse primer 
and 1 μl cDNA sample were put into RT-PCR plates. 10μl of mineral-oil used to cover the surface 
of the mixture. Then the plate was sealed with the plastic wrap and was put into the iCycler 
analyzer.  
3.3.5.4. Quantification of relative expression with respect to GAPDH: Threshold cycles were 
determined using iCycler visualization tools for target and GAPDH gene expression curves. 
Unmodified ΔΔCT method was used by using 2 as the efficiency. The formula of ΔΔCT method is: 
ΔΔCT= (Avg. ΔCT, target - Avg. ΔCT,GAPDH), where ΔCT = (Avg. CT,target - Avg. CT,GAPDH) [79]. 
 
3.3.6 Protein preparation and Western Blot experiments:  
3.3.6.1 Protein extraction: The cell pellet was lysated in the NP40 lysis buffer (explained in 
3.2.4) and vortexed at every 5 min for half an hour and kept on ice during this period. Later lysates 
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were centrifuged at 13000 rpm for 30 min at +4
o
C, the supernatant, which contains the proteins, 
was collected and stored at -80
o
C for quantification by Bradford assay and Western blot 
experiments. 
3.3.6.2 Quantification of protein concentrations: The concentration of cell lysed was detected 
by Bradford assay. 2 μl of protein samples were mixed with 98 μl of ddH2O and then 900 μl of 
Bradford working solution was added to the sample to finalize the volume to 1 ml. For the blank, 2 
μl of NP40-lysis buffer was added to the 98 μl of ddH2O and then 900 μl of Bradford working 
solution was added to this mix. After 5 min of incubation, the protein concentrations were 
measured at OD595 λm versus blank solution. In order to calculate the protein concentrations, a 
standard curve was generated by using different concentrations of BSA protein. 1 mg BSA was 
dissolved in 1 ml of ddH2O to make 1mg/ml BSA concentration. Then, 0, 1, 2, 4, 8, 16, and 32 μl 
of BSA added to 100, 99, 98, 96, 92, 84 and 68 µl of ddH2O, respectively and 900 μl of Bradford 
working solution was put into all of these samples. After 5 min of incubation, the OD595 λm values 
of each samples were measured and the standard curve was prepared with these values. The 
unknown concentrations of the samples were calculated by using this from the standard curve. The 
concentration data of the protein samples are given in Table 4.3.  
3.3.6.3 Western blotting:  
3.3.6.3.1 SDS polyacrylamide gel electrophoresis:  
The gel apparatus was set and resolving and stacking gel solutions (explained at 3.2.4 part) were 
loaded. Equal amounts (50 μg/well) of proteins were mixed with 6X loading dye containing 1% β-
mercaptoethanol and boiled in the water for 5 min to denature the proteins and break S-S bonds. 
Then, samples and Fermentas PageRuler Protein size marker were loaded on gel. Gels were run at 
80 V during until the samples leave the stacking gel and 120 V when the samples were run at 
resolving gel in the 1X running buffer. The run was stopped just after loading dye leaves the gel.  
 27 
3.3.6.3.2 Protein transfer to PVDF Membrane: Since all of our targeted proteins were smaller 
than 120 kDa, semi-dry transfer was performed. Whatman papers and PVDF membranes were cut 
in suitable sizes with gels. The membranes were incubated into 100% methanol for 30 seconds and 
then, immediately merged into ddH2O for 2 min. Later, whatman papers and membrane were 
incubated into the semi-dry transfer buffer for 5 min. Then 2 whatman papers, PVDF membrane, 
gel, and another 2 whatman papers were put on top of each other into the tank. Then the system 
was set to 160mA and the proteins were run for 30 min. 
3.3.6.3.3 Immunological detection of membrane transferred proteins: The membrane was 
incubated with 5% blocking solution for an hour on a slowly rotating platform to get rid of non-
specific bindings. After blocking, the membrane was washed with 0.1% TBS-T three times for 5 
min. The membrane was incubated overnight with primary antibody at +4
o
C on a slowly rotating 
platform, or alternatively incubated at room temperature for 1 hour. After, the membrane was 
washed with 0.1% TBS-T three times for 5 min, the membrane was incubated with HRP-
conjugated secondary antibody together with the primary for an hour at room temperature on a 
slowly rotating platform. Then, the membrane was washed three times with 0.1% TBS-T for 5 min. 
Then, the membrane was treated with ECL plus or FEMTO reagents for 5 min, according to the 
manufacturer’s instructions, and was wrapped with stretch film. The autoradiography was 
performed for various exposure times to obtain the different signal intensities of the labeled 
proteins. 
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CHAPTER 4. RESULTS 
4.1 Determination of optimum time and dose of nicotine treatment 
4.1.1 Nicotine treatment of the SW620 cells and its effect on cell proliferation 
The effect of different nicotine concentrations (10ηM, 100ηM, 1µM, and 10µM) on 
SW620 cell proliferation activity was tested to determine the dose of nicotine and suitable time 
(48h and 7 days) course of the treatment while cells the cells were grown in 10% FBS or 0.1% 
FBS containing culture media. MTT cell proliferation assay was used to test for cell proliferation 
activity. Our findings indicated that SW620 cells were responsive to 0.1% FBS serum-starvation at 
48 hours and 7 days by a reduction of 67% and ca. 99.9%, respectively when compared with 
physiological serum level (Figure 4.1 and Figure 4.2). Nicotine showed a different effect at 0.1% 
and 10% FBS serum levels (Two way ANOVA; P-value (serum) <0.001; P-value (dose) = 0.105). One-
Way ANOVA results demonstrated that nicotine at concentrations starting from 10ηM to 10µM 
consistently rescued the loss of cell proliferative activity while at 1µM concentration nicotine 
exhibited the highest rescue power (Figure 4.1B) under serum-starved conditions at 48 h. No 
effect of nicotine was observed under physiological serum levels (10% FBS) (Figure 4.1A). 
Similarly, cell proliferation activity differed significantly between the cells grown in 0.1% FBS 
and 10% FBS at day 7 (Two way ANOVA; P-value (serum) <0.001; P-value (dose) = 0.922). 
Interestingly, nicotine at 1µM significantly inhibited the cell proliferative activity when compared 
with control at 10% FBS-treated cells, while other doses of nicotine did not affect the cell 
proliferation ratio extensively at day 7 (Figure 4.2A). On the other hand, One-Way ANOVA 
implicated significant induction of cell proliferation in response to all doses of nicotine while 
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100ηM nicotine treated cells exhibited a more significant response (Figure 4.2B) under serum 
starved conditions.  
 
 
Figure 4.1: MTT cell proliferation results for 48h nicotine treated quiescent SW620 colon 
adenocarcinoma cells. A) MTT cell proliferation results for 48h nicotine treated quiescent SW620 
colon adenocarcinoma cells under normal (10% FBS in media) growth conditions. One-Way 
ANOVA were performed to indicate the significance level (F-value = 0.36, DF = 4, P-value = 
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0.835).  B) MTT cell proliferation results for 48 h nicotine-treated quiescent SW620 colon 
adenocarcinoma cells under serum deprived (0.1% FBS in media) conditions. One-Way ANOVA 
findings followed by multiple comparisons were indicated with asterisks (F-value = 8.05, DF = 4, 
P-value = 0.001). Asterisk represents the significantly different sample from other samples. 
(Asterisk with arrows indicates that only samples that were shown by arrows are significantly 
different from each other.) 
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Figure 4.2: MTT cell proliferation results for 7 days nicotine treated quiescent SW620 colon 
adenocarcinoma cells. A) MTT cell proliferation results for 7 days nicotine treated quiescent 
SW620 colon adenocarcinoma cells under normal (10% FBS in media) serum conditions. (One-
Way ANOVA; F-value =1.58, DF = 4, P-value = 0.230). B) MTT cell proliferation results for 7 
days nicotine treated quiescent SW620 colon adenocarcinoma cells under serum deprived (0.1% 
FBS in media) conditions (One-Way ANOVA; F-value = 89.20, DF = 4, P-value < 0.001). 
(Asterisk represents the significantly different sample from other samples. Asterisk with arrows 
indicates that only samples that were shown by arrows are significantly different from each other.) 
 
4.2 Microarray Experiments 
4.2.1 Quality Control of RNA samples and microarray chips 
4.2.1.1 Pre-hybridization quality control of the RNA samples 
To investigate the acute effect of nicotine on the cells, 48 hour treatment time and 1µM 
nicotine dose were used for the microarray experiments to determine the gene expression profile of 
the cells. Accordingly, the RNA samples from the cells grown in 0.1% and 10% FBS containing 
media with or without 1µM nicotine addition were extracted as described in the Materials and 
Methods section (Table 4.1). Initially, RNA sample quality and quantity analyses were performed 
with Agilent 2000 Bioanalyzer and Nanodrop. The results showed that we have high quality RNA 
samples (Table 4.1).  
 
4.2.1.2 Post-hybridization quality control of microarray results 
Post-hybridization quality control analyses also showed that all samples had similar 
degradation slopes (Figure 4.3) and comparable background, 5’3’-GAPDH and ACTIN values as 
well as scaling factors (Table 4.2). 
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Table 4.1: The list of experimental conditions of the SW620 cells and the concentration and RIN 
values of the RNA samples that were prepared for microarray experiments.  
Time 
Course Dosage Serum 
Biological 
Replicate 
Concentration 
(ηg/μl) 
260/280 
value 
RIN 
value 
48h 1μM Nicotine 0.1% FBS Set 2             1913.39 2.12 8 
48h 
No 
Treatment 0.1% FBS Set 2             1039.20 2.07 8.2 
48h 1μM Nicotine 0.1% FBS Set 3 1274.42 2.1 8.4 
48h 1μM Nicotine 10% FBS Set 3 1168.4 2.09 9.6 
48h 
No 
Treatment 0.1% FBS Set 3 668.34 2.11 8.8 
48h 
No 
Treatment 10% FBS Set 3 727.7 2.11 9.7 
 
 
A  
 33 
B  
Figure 4.3: Representative figures for microarray hybridization quality control results for 10% 
FBS treated control samples (For the whole list, Appendix C). A) Quality Control (QC) plot. The 
QC plot represents the QC metrics for arrays within each class. Within each class, each array is 
represented by a segment of the image. The scale factor for each array is plotted as a horizontal 
line from the vertical zero-fold line to the solid point that represents the scale factor. Scale factors 
in blue are within the three-fold range and those in red are out of range. The circle and triangle 
points represent GAPDH and B-ACTIN ratios, respectively. B) RNA degradation plot. The RNA 
degradation plot represents the scaled mean intensity for 5’ to 3’ probes. Each line represents an 
array within a class. The consistent slopes of arrays within a class indicate good quality 
(http://linus.nci.nih.gov/BRB-ArrayTools.html). 
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Table 4.2: Representative data for microarray post-hybridization quality control analysis. The 
background found to be comparable for 5’3’-GAPDH and ACTIN values as well as scale factors. 
Samples %Present  
Scale 
Factor  b.Actin3.5  GapDH3.5  b.Actin3.M  GapDG3.M  
Avg. 
Background  
0.1% FBS 
Control Set3 47.36 0.38 0.57 0.33 0.03 0.16 59.42 
0.1% FBS 
Control Set2 47.09 0.57 1.25 0.67 0.10 0.22 44.82 
0.1% FBS 1uM 
Nicotine Set3 49.38 0.42 1.15 0.54 0.36 0.30 45.60 
0.1% FBS 1uM 
Nicotine Set2 49.19 0.41 0.57 0.25 0.07 0.22 43.16 
10% FBS 
Control Set3 45.93 0.39 0.25 0.16 -0.06 0.08 47.80 
10% FBS 1uM 
Nicotine Set3 46.27 0.45 0.30 0.19 -0.02 0.11 47.57 
 
 All analyses indicated that the six arrays performed in this study were comparable.  
 
4.2.2 Scatter plot analysis  
We performed scatter plots of the microarray data to see the extent of dispersion between 
groups of treatments at fold-change level (i.e., 2). Accordingly, we also aimed to see the 
distribution of these genes in scatter plots to compare the effects (upregulation or downregulation, 
respectively) of normal serum and nicotine exposure under different serum levels (Figure 4.4 and 
Figure 4.5). 
 According to the results of scatter plots, there are more genes upregulated by nicotine than 
those downregulated in response to nicotine treatment at 0.1% FBS level (Figure 4.4A and Figure 
4.5A). Moreover, these genes were also upregulated or downregulated in response to addition of 
serum (10% FBS) in a fashion mimicking the effects of nicotine under serum starvation (Figure 
4.4B and Figure 4.5B). Although these genes similarly acted in normal serum condition in 
comparison to the nicotine treatment under serum deprivation, when we compared the 10% FBS 
treatment with nicotine treatment under serum starvation, we saw that these genes although much 
less in number were greatly downregulated at 10% FBS (Figure 4.4C). A similar distribution was 
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also apparent in the nicotine-mediated downregulation profiles (Figure 4.5C). We also compared 
the effects of nicotine at 10% FBS levels; our results indicated the extent of modulation by 
nicotine was relatively small when compared with that observed under serum starvation, however 
there were a number of genes that were located closely at the fold change threshold indicating that 
a part of the nicotine-response under serum starvation might still exist at 10% FBS levels, although 
mildly (Figure 4.4D and Figure 4.5D). 
 
 
Figure 4.4: Different Scatter plot illustrations of 1μM nicotine exposed samples’ downregulated 
genes in 0.1% FBS control in comparison with 1μM nicotine under same serum conditions. A) Red 
dots indicate downregulated genes in 0.1% FBS treatment in comparison with 1μM nicotine under 
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same serum conditions. B) Box-B represents the locations of significant genes in box A under 10% 
FBS control compared to 0.1% FBS control. C) Box-C represents the locations of significant genes 
in box A under 10% FBS control compared to 0.1% FBS 1μM Nicotine treated sample. D) Box-D 
represents the locations of significant genes in box A under 10% FBS control compared to 10% 
FBS 1μM nicotine treated sample. 
 
Figure 4.5: Different Scatter plot illustrations of 1μM nicotine exposed samples’ 
upregulated genes in 0.1% FBS control in comparison with 1μM nicotine under same serum 
conditions. A) Red dots indicate upregulated genes in 0.1% FBS treatment in comparison with 
1μM nicotine under same serum conditions. B) Box-B represents the locations of significant genes 
in box A under 10% FBS Control compared to 0.1% FBS control. C) Box-C represents the 
 37 
locations of significant genes in box A under 10% FBS Control compared to 0.1% FBS 1μM 
Nicotine treated sample. D) Box-D represents the locations of significant genes in box A under 
10% FBS Control compared to 10% FBS 1μM Nicotine treated sample. 
 
4.3 Determination of differentially expressed gene profiles upon nicotine exposure under 
different serum conditions after microarray analyses 
4.3.1 Statistical and functional analysis of nicotine response 
In order to see the effects of nicotine under serum starvation in comparison with the effects of 10% 
FBS addition, we performed a gene set enrichment analysis regarding the significant KEGG 
pathways (Appendix B); thus we filtered out the significant genes at p<0.05 (over 800) that were 
up- or down-regulated under nicotine treatment to illustrate the interactions of the genes in terms 
of cellular regulatory and metabolism pathways with the help of Pathway Miner. In the following 
graphs, upregulated and downregulated genes (with greater or less than 1.5 fold change, 
respectively) were represented by red and green coloring. The gene clusters involved in both 
cellular and metabolic pathways were shown in Figure 4.4. The most striking interactions 
belonged to cell cycle, calcium signaling, purine/ pyrimidine metabolism, cell adhesion, cell 
communication, estrogen metabolism, coagulation and ribosomal proteins interactions (Figure 
4.6; Appendix B). 
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Figure 4.6: KEGG Pathway illustrations sketched via significant genes of 10% FBS serum 
conditions and 1μM Nicotine treatment in comparison with 0.1% FBS serum treatments. A) The 
genes affected by 1μM nicotine treatment under starvation conditions in comparison with 
starvation controls. B) The genes affected by normal serum conditions compared to serum 
starvation. The different intensities of green and red colors represent the strength of 
downregulation and upregulation of the normal serum or 1μM Nicotine genes in comparison with 
serum starvation, respectively. 
 
We also specifically focused on cellular regulatory process pathways (Figure 4.7) and 
metabolic pathways (Figure 4.8). The cell cycle, calcium and MAPK signaling, coagulation, cell 
communication, cell adhesion, ribosomal machinery proteins, Alzheimer related genes, and Notch 
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signaling genes were extensively regulated by nicotine under serum starvation conditions in 
cellular regulatory pathways, which also mimicked the response to 10% FBS in terms of these 
pathways (Figure 4.7). Similarly, estrogen metabolism, amino acid metabolism and biosynthesis, 
glycan biosynthesis, glycolipid metabolism and purine/ pyrimide metabolism were regulated by 
nicotine in terms of KEGG metabolic pathways (Figure 4.8; Appendix B). 
 
 41 
 
 
 
Figure 4.7: The Cellular and Regulatory Process Pathways were illustrated via KEGG Pathway 
representing significant genes of 10% FBS serum conditions or 1μM Nicotine treatment in 
comparison with 0.1% FBS serum treatments. A) The genes affected by 1μM nicotine treatment 
under starvation conditions in comparison with starvation controls. B) The genes affected by 
normal serum conditions compared to serum starvation. The different intensities of green and red 
colors represent the strength of downregulation and upregulation of the normal serum or 1μM 
Nicotine genes in comparison with serum starvation, respectively. 
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Figure 4.8: The Metabolic Pathways were illustrated via Pathway Miner using KEGG Pathway 
genes representing significant genes of 10% FBS serum conditions or 1μM Nicotine treatment in 
comparison with 0.1% FBS serum treatments. A) The genes affected by 1μM nicotine treatment 
under starvation conditions in comparison with starvation controls. B) The genes affected by 
normal serum conditions compared to serum starvation. The different intensities of green and red 
colors represent the strength of downregulation and upregulation of the normal serum or 1μM 
Nicotine genes in comparison with serum starvation, respectively. 
Among the pathways mentioned above, we decided to focus on some of them separately to 
identify candidate genes affected by nicotine. Cell cycle pathway genes were one of the 
preferences regarding the nicotine effect. The class comparison analyses as visualized in Pathway 
Miner indicated that nicotine upregulated the genes included processes like DNA replication and 
cell division such as cell cycle genes (e.g., Cyclin E1, A1, B1), CDCs (cell division cycle genes), 
PCNA (Proliferating cell nuclear antigen), MCM5 (DNA helicase) (Figure 4.9, Appendix A1). 
Furthermore, ATR (Ataxia telangiectasia and Rad3 related) and CDKN2A (Cyclin dependent 
kinase inhibitor 2A) that results in cell cycle arrest, were strikingly downregulated by nicotine 
treatment under serum starvation conditions (Figure 4.9A). 
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Figure 4.9: The cell cycle pathway genes illustrated via Pathway Miner with KEGG pathway 
genes. A) The genes affected by 1μM nicotine treatment under starvation conditions in comparison 
with starvation controls. B) The genes affected by 10% serum conditions compared to serum 
starvation. The different intensities of green and red colors represent the strength of 
downregulation and upregulation of the normal serum or 1μM Nicotine genes in comparison with 
serum starvation, respectively. 
 
Ribosomal protein genes were also detected as deregulated genes via nicotine treatment. 
Many of the ribosomal (RPLs, RPSs) protein genes had smaller fold-changes (under 1.5), but the 
rest of the ribosomal proteins were significantly downregulated in both nicotine treatment and 
normal conditions (Figure 4.10). Only one gene, MRPL13, which is mitochondrial, was slightly 
upregulated (Figure 4.10). 
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Figure 4.10: The ribosomal protein interactions illustrated via Pathway Miner with KEGG 
pathway genes. A) The genes affected by 1μM nicotine treatment under starvation conditions in 
comparison with starvation controls. B) The genes affected by 10% serum conditions compared to 
serum starvation. The different intensities of green and red colors represent the strength of 
downregulation and upregulation of the normal serum or 1μM Nicotine genes in comparison with 
serum starvation, respectively. 
 
 One of the most interesting pathways was Ca
2+
 signaling pathway for the differential role 
of nicotine exposed to serum deprived cells in comparison with normal conditions. Although other 
pathways had the significant expression differences on the same genes, the differentially expressed 
Ca
2+
 signaling pathway genes were different under nicotine treated serum starvation condition in 
comparison with physiologic serum conditions (Figure 4.11).While NOS3 and TTPR1 were 
upregulated and GNAS, NPR2, TTPR2 and PPP3CA genes were downregulated under nicotine 
treatment (Figure 4.11A), MAPT, GNAS, NPR2 were downregulated and PPP3R1 gene was 
upregulated in response to 10% serum (Figure 4.11B). 
 
Accordingly, purine/ pyrimidine metabolism was another very affected pathway due to 
nicotine treatment in serum deprivation conditions and normal physiological conditions of the 
SW620 cells. Similar genes were upregulated or downregulated in both conditions (Figure 4.12). 
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Figure 4.11: The Calcium Signaling genes illustrated via Pathway Miner with KEGG pathway 
genes. A) The genes affected by 1μM nicotine treatment under starvation conditions in comparison 
with starvation controls. B) The genes affected by 10% serum conditions compared to serum 
starvation. The different intensities of green and red colors represent the strength of 
downregulation and upregulation of the normal serum or 1μM Nicotine genes in comparison with 
serum starvation, respectively. 
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Figure 4.12: The Purine/ Pyrimidine metabolism illustrated via Pathway Miner with KEGG 
pathway genes. A) The genes affected by 1μM nicotine treatment under starvation conditions in 
comparison with starvation controls. B) The genes affected by 10% serum conditions compared to 
serum starvation. The different intensities of green and red colors represent the strength of 
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downregulation and upregulation of the normal serum or 1μM Nicotine genes in comparison with 
serum starvation, respectively. 
 
Another interesting metabolism pathway was glucuronidation pathway in which the genes 
were significantly upregulated under nicotine treatment in comparison with normal conditions 
(Figure 4.13). The genes (Uridine 5'-diphospho-glucuronosyltransferases 1A- UGT1As) have 
been shown to be very important in the body's elimination of foreign substances such as drugs and 
medications, as well as endogenous substances including endogenous toxins [80]. One of the genes 
of this family, UGT1A6, was very interesting such that it was highly upregulated in nicotine 
treated serum but was detectably downregulated under physiological serum conditions (Figure 
4.13). 
A          B  
Figure 4.13: The Glucuronidation metabolism illustrated via Pathway Miner with KEGG 
pathway. A) The genes affected by 1μM nicotine treatment under starvation conditions in 
comparison with starvation controls. B) The genes affected by10% serum conditions compared 
to serum starvation. The different intensities of green and red colors represent the strength of 
downregulation and upregulation of the normal serum or 1μM Nicotine genes in comparison 
with serum starvation, respectively. 
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 DNA polymerase activity was also observable in nicotine treated serum starvation 
conditions; however, the upregulation of DNA polymerase genes was much higher in response 
to addition of serum, expectedly (Figure 4.14). 
 
A B  
Figure 4.14: DNA polymerase genes illustrated via Pathway Miner with KEGG pathway genes. 
A) The genes affected by 1μM nicotine treatment under starvation conditions in comparison with 
starvation controls. B) The genes affected by 10% serum conditions compared to serum starvation. 
The different intensities of green and red colors represent the strength of downregulation and 
upregulation of the normal serum or 1μM Nicotine genes in comparison with serum starvation, 
respectively. 
 
4.3.2 Effects of serum and of nicotine on cholinergic receptor expression 
Nicotine did not have significant effects on cholinergic receptor expression except that CHRNA1 
expression was greater under nicotine treatment when cells were serum-starved while the same 
increase was not observed under physiological serum concentrations (p-value <0.05, 
CHRNA1mean= 5.98 (10% FBS control), 5.88 (10%FBS 1µM Nic),  6.30 (0.1% FBS Control),  
7.31 (0.1% FBS 1µM Nic )) (Figure 4.15). On the other hand, CHRNA5 was the most 
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significantly affected receptor among other followed by CHRNE in response to serum (p-value < 
0.05, CHRNA5geoMean= 8.58 (10% FBS) and 7.02 (0.1% FBS); CHRNE geoMean= 7.10 (10% FBS) 
and 6.66 (0.1% FBS)) (Figure 4.15).  
 
Figure 4.15: Treeview image of nicotinic cholinergic receptor genes’ expression profiles.  
Nicotine has significant effect on the cluster of CHRNs but has not very noteworthy effect on 
the receptors individually. Red and green colors indicate a reduction and induction of 
expression when each gene is normalized to its median. 
 
4.3.3 Microarray verification experiments of selected differentially expressed genes using 
real-time RT-PCR and Western Blot analyses 
Western blot experiments were performed to see whether we can observe the similar expression 
pattern we obtained using the microarray profiling also at the protein level. For that purpose, we 
used Bax protein (a pro-apoptotic gene) levels; under normal serum conditions the protein levels 
decreased via nicotine treatment. When cells were deprived of serum the protein level increased 
drastically as expected yet but BAX protein expression was totally lost when cells were treated 
with nicotine together with serum deprived media (Figure 4.16).  In the case of p53, the protein 
levels considerably decreased under serum starved condition when nicotine was present in media 
in comparison with the control samples. The level of this protein as expected did not change very 
momentously under normal serum conditions (Figure 4.16). The cell cycle regulator CYCLIN E 
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protein levels on the other hand, did not change drastically yet it is possible that under serum 
starvation the level of this protein might have been slightly induced by nicotine. 
 
Table 4.3: 48 hours with or without 1 μM nicotine exposed SW620 cells’ total protein 
concentration values calculated via Bradford technique after isolation. 
Protein Sample ID 
Concentration 
(μg/μl) 
48h 10% FBS Control Set2 16.3 
48h 10% FBS 1μM Nicotine Set2 14.3 
48h 10% FBS Control Set3 7.6 
48h 10% FBS 1μM Nicotine Set3 7.4 
48h 0.1% FBS Control Set2 3.7 
48h 0.1% FBS 1µM Nicotine Set2 5.5 
48h 0.1% FBS Control Set3 6.1 
48h 0.1% FBS 1μM Nicotine Set3 5.7 
 
 
Figure 4.16: Western blotting results of 48 hour 1µM nicotine treated SW620 cells under two 
different serum conditions.  
 
To confirm microarray experiment results, we first identified candidate genes by using 
Class comparison method. XIAP and Survivin were two significant candidates for our purpose and 
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we used GAPDH as a control (house-keeping gene) according to our microarray results (Figure 
4.17). Therefore, we performed a qRT-PCR experiment with XIAP and Survivin, anti-apoptotic 
genes, together with the control gene GAPDH (Figure 4.18 and 4.19, respectively). According to 
these qRT-PCR results, under normal serum conditions neither XIAP nor Survivin have any 
noteworthy differential expression in comparison with what was observed with nicotine exposure 
under normal serum treated controls (preliminary data). However, under serum deprivation, 
nicotine treatment drastically increased the expressions of both of the genes. The expression 
difference was much stronger for the SURVIVIN gene. When these cells were deprived of serum, 
SURVIVIN expression was almost totally lost, but when nicotine was provided to the cells, the 
expression level of the SURVIVIN gene increased dramatically, even when compared to the levels 
obtained under normal serum conditions (Figure 4.19). 
 
Figure 4.17: Treeview imaging of SURVIVIN and XIAP gene expression values from 
microarray analyses together with GAPDH. The red and green color intensity expresses the 
upregulation and downregulation of gene expression values, respectively. 
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Figure 4.18: qRT-PCR results of XIAP (anti-apoptotic gene) under different conditions. 
GAPDH used as an internal control for qRT-PCR. 
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Figure 4.19: qRT-PCR results of SURVIVIN (anti-apoptotic gene) under different conditions. 
GAPDH used as an internal control for qRT-PCR. 
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CHAPTER 5. DISCUSSION and CONCLUSION 
In the USA, colorectal cancer is the third most common cite of new cases and deaths in both men 
and women [13]. An individual’s lifetime risk of developing colorectal cancer in the US is 
approximately 6%, with 90% of these occurring after age 50 [81]. Nearly 90% of all colorectal 
cancers and deaths are estimated to be preventable based on symptoms and early detection of 
polyps. As the symptoms of the colorectal cancer are not rapidly seen but very slowly developing, 
thus cancerous tissue cannot be diagnosed at the very early stages of the tumor. Therefore, it is 
important to investigate candidate genes and signaling pathways for their diagnostic potential with 
further implications on prognosis, as well. There are many risk factors for colorectal cancer. 
Genetic reasons (family history), physical inactiveness, red meat consumption, obesity, ulcerative 
colitis, Crohn’s disease, alcohol and smoking are significant risk factors for this disease. Family 
history and physical inactivity have the highest relative risk ratios with 1.8 and 1.7, respectively 
[81]. Smoking has the next highest ratio with 1.5, meaning that smoking is one of the very crucial 
leading factors for colorectal cancer.  
Tobacco does not only associate with colorectal cancer, but also 30% incidences of all 
cancer types, in which oral and lung cancer rates are higher than this rate, are directly related to 
smoking. Consequently, there are a lot of studies regarding tobacco and its ingredients. Nicotine is 
an active-alkaloid in tobacco and it is the strongest addictive chemical by which the dopaminergic 
system is deregulated in brain. Although there are many studies with nicotine’s effect on cancer 
formation in lung, larynx, and oral cancer, only few studies are present regarding colorectal cancer 
cells and the action of nicotine through key genes modulated by nicotine exposure. Hence, these 
reasons led us to study the activity of nicotine upon colon cancer cells. 
In this study, the cell proliferative and apoptotic effects of nicotine were studied using 
MTT assays, Western Blots, microarray transcription profiling and real-time RT-PCR studies. Our 
findings indicated that nicotine exhibited drastic proliferative effects under serum starvation 
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conditions but did not have a significant role in cell proliferation under normal growth conditions 
at different time courses (48 hour, 7 days, 15 days (data not shown)).  
In terms of the design of the microarray and confirmatory experiments, we have used a 
1µM as the optimum dose. Although all small concentrations of nicotine significantly play a role 
in cell proliferation, nicotine at 1µM closely resembles the higher limit of the concentration 
(0.025- 0.444 µM/ ml) of nicotine found in the blood of women and men (3-18 year-smokers) [82, 
83]. Moreyra et al. also have shown that after the first two cigarette smoked, the nicotine 
concentration increases to 45 ± 8 ηg/ml (ca. 400 µM/ml) in the blood [84]. Therefore, 1µM 
nicotine concentration for 48 hour exposure to SW620 cells seems to be an optimum condition to 
assess the acute and early gene expression regulation of nicotine. 
5.1 Nicotine Regulated Cell Proliferation and Cell Cycle 
Since unstoppable cell proliferation and division is the most important feature of tumor 
development serum starvation does lead to cell cycle arrest and ceases the cell proliferation. When 
we examined the effects of nicotine under serum starvation conditions, nicotine seemed to have a 
definite role in rescuing from loss of cellular proliferation. Alongside with our MTT experiment 
data (Figures 4.1 and 4.2), microarray pathway analyses and further verification with Cyclin E 
RNA and protein levels coming from the class comparison we could propose that nicotine at 1µM 
systematically modifies the cell cycle machinery at both the RNA and protein levels. In contrary to 
the significant increase of cell proliferative genes under serum starvation conditions upon nicotine 
treatment, under normal conditions nicotine has not significant effect on the expression of these 
gene families (Appendix A1, Figure 4.9). This may be due to the competition of nicotine with 
other growth factors and subsequent proliferative effects. Indeed, the recurrent exposure to 
nicotine enhances the activity of EGFR in bronchial epithelial cells which are finally differentiated 
[85]. Moreover, nicotine also activates VEGF-C gene alongside the EGFR level in cervical cancer 
cells [86]. These results can be interpreted as nicotine might exhibit a growth factor like behavior 
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and nicotine exposure deregulates intracellular signaling pathways as if they have got stimuli from 
a growth factor. When there is enough growth factor in the media, nicotine may not have a 
significant acute activity (48 h) in terms of cell growth; however, it does have a very striking act 
on serum starved cells in order to force them to proliferate and grow. Another possibility, and not 
necessarily mutually exclusive, would be that nicotine initiates receptor activity through binding to 
its own receptors and recruits Rb-Raf-1 and c-src pathways via β-arrestin [53]. Although this has 
been shown in lung cancer cells colon cancer cells have not been studied in this context. 
5.2 Nicotine Mediated Apoptosis  
Besides cell proliferation, apoptosis is another key mechanism in cancer development. Normally, 
cancerous tissues lose their feature of entering apoptosis and they start to proliferate ad infinitum. 
This is sometimes because of a repressive mutation of a tumor suppressor- apoptosis triggering 
gene (as in the case of p53 mutations), or an over expression of a proto-oncogene (as c-myc). It is 
worth noting that tumorigenesis due to non-apoptotic features does generally not depend on a 
single gene mutation, but it requires multiple hits along with some epigenetic deregulations [87, 
88]. In addition, as apoptosis is triggered by serum starvation [89], it is essential to investigate 
whether the nicotine activity under different serum conditions result in changes in the RNA and 
protein levels of apoptotic and/or anti-apoptotic genes. Although XIAP expression significantly 
increased under serum starvation conditions by nicotine treatment, one important difference from 
Survivin’s behavior grasped the attention. Survivin’s expression was lost under serum starvation 
while that of XIAP was relatively higher when compared with XIAP expression at 10% FBS. 
However, nicotine increased expression of both genes, especially under serum starvation. This 
unexpected increase observed with XIAP expression under serum starvation may be due to the fact 
that XIAP could stop apoptosis induced either by viral infection or overexpression of primary cell 
death genes, caspases [90] via binding caspase 3, 7 and 9 [91]. Wilkinson et al. showed that 
deregulation of XIAP results in autoimmunity, neurodegenerative disorders and cancer [92]. This 
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result may be one of the explanations for heightened expression of XIAP under serum deprivation. 
Although deprived of serum, cancer cells might inherently increase XIAP which may have such a 
function to prevent cells from apoptosis at any cost. Moreover, in the development of lung cancer, 
the overexpression of XIAP not only inhibits caspase, but also stops the activity of cytochrome c 
(caspase activator) [90]. Therefore, it means that it interrupts the activity of mitochondria which is 
the energy supplier organelle of the cells. Taken together, XIAP can be resembled a blind-Samurai 
that fights for its rights at any cost by forcing cells not to enter the apoptosis when normal cells 
would. It would be interesting to perform similar experiments with normal colon cells under serum 
deprivation with or without nicotine exposure to see whether normal colon cells could escape this 
force. 
In addition to real-time analyses of XIAP and SURVIVIN expression, changes of protein 
levels of Bax and p53 confirmed our findings obtained from the MTT results, the two apoptotic 
markers of cellular response were drastically downregulated in the presence of nicotine. It is 
known that nicotine induces cell proliferation in association with p53 down-regulation [93]. 
Moreover, according to a study regarding lung cancer and smoking relation in terms of p53 
mutation it was shown that in lung cancers, the p53 mutational patterns differ between smokers 
and nonsmokers. such that smokers have frequent G to T transversions [94]. Besides p53, 
proapoptotic protein Bax expression was shown as downregulated by nicotine via inducing Bax 
phosphorylation and nicotine blocked stress-induced translocation of Bax from cytosol to 
mitochondria in lung cancer cells [34]. Although these studies suggests novel mechanisms 
regarding nicotine and apoptosis triggering proteins in different cell lines via using different 
approaches like triggering apoptosis via cisplatin, our study is the first showing nicotine also 
regulates the protein levels of these two proteins in SW620 cells. 
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5.3 Nicotine Effects upon Nicotinic Acetylcholine Receptors in SW620 
As it has been mentioned in the introduction part, nicotine exerts its activity via nAChR [61]. 
nAChR forms hetero-pentamers on the cell membrane, although there are some preferred 
complexes such as nAChRα7 homo-pentamer or nAChRα4β2 pentamer in neuronal cells [52]. The 
regulation of nAChR subunit expressions is important for nicotine activity. To clarify the 
molecular mechanisms that are affected by nicotine, nAChRs should be well identified and 
discussed. As cholinergic receptors behave similar to each other in terms of receptor activity, they 
may have similar gene expression patterns and may have common regulatory elements (promoters, 
enhancers). To see their gene expression profile in response to serum deprivation and nicotine 
exposure, we filtered the nAChR probe sets from normalized microarray data and we obtained the 
gene expression values before clustering these genes for determination of coexpression tendency in 
terms of serum and nicotine conditions. As a result, nAChR genes did not change drastically with 
regard to serum addition and nicotine activity, except nAChRα5 (Figure 4.17).  nAChRα5 
significantly was affected by serum starvation and under poor serum conditions, nAChRα5 
expression decreased independent of nicotine treatment in the SW620 cells. If we look at the heat 
map carefully, we can interpret that nAChRα5 has a very strong role in classifying normal serum 
treated samples versus serum deprived samples. On the other hand, nACHRα1 responded to 
nicotine under serum starvation. Previous studies classified the expression of lung cancer cell lines 
in terms of expression of nACHRs. No studies exist for the expression of nACHRs under serum 
starvation or nicotine exposure in colon cancer. Moreover, this is the first study that implicates 
nACHRα5 and α1 as differentially modulated genes by nicotine/ serum. Another interesting 
feature of the cluster analysis was that although nAChR genes have not strong expression values 
except nAChRα5, they can separate and cluster nicotine exposed samples and control samples 
under serum deprivation conditions. This suggested that although nicotine has not significant effect 
upon nAChR genes individually under serum depletion conditions, it actually may modulate the 
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cluster as a whole as if they were one. This suggestion also strengthens that nAChR genes may 
have common regulators at the transcriptional level.  
5.4 Nicotine and Signaling Pathways 
According to our Gene Set Enrichment Analysis and Pathway Miner studies of microarray 
experiments, many different signaling pathways including cell cycle, calcium signaling, cell 
adhesion, cell communication, ribosomal protein activity, purine/ pyrimidine metabolism, 
Alzheimer disease genes, and glucuronidation pathway genes were found to be modulated 
(Appendix B). Effect of nicotine on cell cycle regulation has been demonstrated in many 
previous studies [53, 78]. Accordingly, our data shows that in the nicotine-treated serum 
starved SW620 cells, the genes (like cyclins and CDCs) that support cell division were 
upregulated but the inhibitors (eg. ATR and CDKN2A) were downregulated and the expression 
profiles of these genes were significantly similar to the profile of normal serum treated cells. 
This may mean that nicotine may trick the starved cells as if they were not starving and force 
them to divide. The commitment to mitosis by nicotine exposure may result in tumor formation 
in normal cells and may result in malignancy and aggressiveness of benign tumors.  
Other than cell cycle deregulation, nicotine also acts on ribosomal proteins’ expression 
and regulation. According to our results of Pathway Miner, nicotine exposed serum starved 
cells and 10% serum treated cells act in parallel in terms of ribosomal protein expression 
profiles meaning both of these two conditions result in the down regulation of ribosomal 
protein encoding genes. Ribosomal proteins (RPs) are fundamental components, which 
assemble with four rRNA throughout a complex mechanism that takes place at different sites of 
the cell (nucleolus, nucleoplasm, cytoplasm, respectively), of ribosomes [95]. For a long time it 
was thought that RP regulation were controlled by growth factors, but recently different studies 
indicated that there are also some key signaling pathways that take place in RP mRNA 
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expression and translational regulation as PI3K, NK-κB, c-Myc and mTOR [96-99]. Although 
ribosome deficiencies due to RP gene mutations have been known for many years in 
Drosophila and Xenopus [100, 101], the scientists did not pay attention to these small proteins 
which were only considered as non-crucial subunits that play roles in formation of ribosome. 
But recent studies show that RP deregulation and mutations may result in very important 
defects. For instance, RPS6 conditional knock out in the liver of the mouse causes cell cycle 
block [102]. Besides, according to a very recent study RPL11 knock out experiments in 
zebrafish show that this gene is very important for embryonic development and its absence 
results in abnormalities in the brain and finally causes death through p53 dependent apoptotic 
response [103]. This protein also negatively regulates oncoprotein MDM2 via p53-dependent 
pathway [104]. Moreover, RPL11, RPL5, RPL23 and RPS7 were shown as MDM2 regulators 
via inhibiting its E3 ligase activity toward p53 tumor suppressor protein [105, 106]. Another 
RP protein, RPS3, was shown that its mRNA level is elevated in colorectal tumors [107], 
besides RPL15 and RPL19 in gastric cancer, and RPL7a and RPL37 in prostate cancer [108]. 
Nicotine has reduced RP expression to closer to the levels attained by the addition of 10% 
serum suggesting that nicotine and serum both might rescue from apoptosis/growth arrest 
induced by RP over-expression. The ribosomal protein genes such RPL10, RPS23, RPS11 and 
RPL36 are greatly downregulated via nicotine and they can be very important agents in terms 
of anti-cancer drug treatments.   
 In addition, nicotine treated serum starvation cells had upregulated genes in DNA 
polymerase activity and purine/ pyrimidine metabolism. The upregulation of these genes again 
supports that when cells under serum starvation, meaning poor growth factors in the media, 
nicotine mediates growth factor-less cell proliferation which may be possible via cell division 
without cell growth. This can be tested by enzymatic activities of growth and cell division 
regulating enzymes. 
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 Another interesting data came up with the “Glucuronidation metabolism”, in which 
UDP-glucuronosyltransferase (UGT), a glycosyl transferase catalyzes the reaction [109]. This 
reaction basically involves addition of the sugars to lipids and to the other apolar xenobiotics 
and is an important step in the organism’s elimination of foreign substances such as xenobiotic 
metabolism of substances such as drugs, pollutants, bilirubin, androgens, estrogens, 
mineralocorticoids, glucocorticoids, fatty acid derivatives, retinoids, and bile acids as well as 
endogenous substances including endogenous toxins [110]. The genes belong to this metabolic 
pathway were significantly upregulated under nicotine treated serum starvation circumstances, 
in comparison with the addition of 10% serum. Although in the previously mentioned pathways, 
the gene expression profiles of nicotine treated serum starvation and of normal serum treated 
cells were acting in parallel, the genes of glucuronidation were totally acting in the opposite 
direction. The most significant gene, UGT1A6, was strongly upregulated under nicotine treated 
serum deprivation, but drastically downregulated under physiological serum conditions. 
Although there are not much study regarding UGT1A6 and colorectal cancers, it was shown 
that UGT1A6 variants influence colorectal carcinogenesis neoplasia recurrence and decreases 
the risk of recurrence [111]. This data may be important in terms of showing that UGT family 
(especially UGT1A6) genes have important role in tumorigenesis prevention. According to our 
data UGT1A6 upregulation under nicotine exposed serum starvation condition may show that 
UGT1A6 may specifically target nicotinic effect in the cell. Therefore, UGT1A6 may be a very 
important for repressing nicotine deregulation of the cell signaling.  
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CHAPTER 6. FUTURE PERSPECTIVES 
In the present study, we showed that 1µM nicotine regulates cell proliferation under serum 
starvation conditions via deregulating many different families of genes (Section 4.1.2). The future 
studies regarding the results of this project will focus on the molecular mechanisms of the 
significantly regulated genes by nicotine. 
One of the future perspectives will be the understanding the nicotine and nAChRs 
relationship in the colon cancer cell lines. Although we showed that nicotine has a proliferative 
effect on SW620 cell lines under serum starvation conditions, we do not know that which subunits 
of nAChRs are important for nicotine activity. Even, we do not know surely that whether nicotine 
act only through these receptors. Therefore, experiments regarding the inactivation of nAChRs 
should be done. The common ligand binding domains of these receptors can be blocked by 
chemical drugs and this may prevent nicotine binding. Another approach may be using siRNA 
technique to silence specific nAChRs and see whether nicotine activity differs. nAChRα1 and 
nAChRα5 are two good candidates for siRNA experiments. On the contrary, also these candidate 
receptors can be overexpressed in the colon cancer cells and nicotine effect can be compared to the 
receptor silenced or normal cell behavior.  
Another future approach may be using different cancer cell lines in order to screen 
nicotine’s effect on different cancer types. In addition, normal cell lines should be exposed to 
nicotine and compared to cancer cells in terms of cellular activity and cell proliferation targeting 
specifically regulated genes by nicotine according to this study. As we studied with only one type 
of colon cancer cell, some part of our results may be specific to SW620 cell line and in order to get 
a more reliable data about nicotine and activity on colon cancer/tissue, using many different types 
of cells can be a good idea. 
As it was mentioned before, nicotine regulates apoptosis and may downregulate important 
proapototic genes (such as Bax). Although we showed that nicotine has a obvious effect on these 
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kinds of genes via real time RT-PCR and western blot (although these experiments are 
preliminary) with SW620 colon cancer cells, we did not test nicotine’s activity against other 
apoptotic conditions such as UV and drug treatment. Therefore, it would be a very good approach 
to trigger apoptosis and then test the nicotine effect in terms of rescuing cells from apoptosis via 
different experimental setups like TUNEL assay, FACS analysis, caspase assays or using different 
apoptosis detection kits.  
Throughout our microarray analyses, we showed that there are thousands of genes affected 
by nicotine activity under serum starvation conditions, more replicates of each condition may be 
necessary for conclusive results. Furthermore, there many interesting gene families arose as targets 
of nicotine under serum starvation; among these genes are proteasomes, ribosomal proteins, 
specific miRNA targets, cell cycle genes, MAPK signaling genes. Candidate genes will be selected 
among this rich informative data and they will be used in order to catch some key features to 
enlighten the mechanisms that are regulated by nicotine.  
In addition, different time courses for nicotine exposure may help to understand the 
behavior of nicotine under short and long times. As cancers do not develop rapidly but it takes 
years to develop a tumor on a tissue, treating the cells with small concentrations of nicotine for 
very long periods may give better ideas about nicotine role in development of colon cancer. For a 
starting experiment, nicotine treatment for 7 days microarray experiments can be considered as a 
further step to the 48 h microarray experiments as we have very significant results at 7 days under 
nicotine treatment in serum starved cells.
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APPENDICES 
APPENDIX A: The results of the gene set enrichment analysis of the significant gene lists 
that generated by comparing the expression profiles of the nicotine treated serum starved 
cells to the cells grown under physiological serum level 
Appendix A1: The significant genes act in biological process pathways. The significant 
genes, of nicotine effect in comparison with serum starvation, act in biological process, listed 
according to the results of gene set enrichment analysis of comparison of nicotine treated 
samples with serum starvation conditions. The figure generated via "Webgestalt" tool. The 
pathways shown in red represent significance statue (p-value<0.05). 
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Appendix A2: The significant genes act in cellular component pathways. The significant 
genes, of nicotine effect in comparison with serum starvation, act in cellular component, listed 
according to the results of gene set enrichment analysis of comparison of nicotine treated 
samples with serum starvation conditions. The figure generated via "Webgestalt" tool. The 
pathways shown in red represent significance statue (p-value<0.05). 
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Appendix A3: The significant genes act in molecular function pathways. The significant 
genes, of nicotine effect in comparison with serum starvation, act in molecular process, listed 
according to the results of gene set enrichment analysis of comparison of nicotine treated 
samples with serum starvation conditions. The figure generated via "Webgestalt" tool. The 
pathways shown in red represent significance statue (p-value<0.05). 
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APPENDIX B: The KEGG pathway list of the significant genes that are generated by 
comparing the expression profiles of the nicotine treated serum starved cells to the 
untreated serum starved cells by the gene set enrichment analysis 
  
Kegg 
Pathway Pathway description 
Number 
of 
genes 
LS 
permutation 
p-value 
KS 
permutation 
p-value 
1 hsa03010 Ribosome 219 0.00001 0.00001 
2 hsa04110 Cell cycle 274 0.00001 0.00076 
3 hsa04940 Type I diabetes mellitus 123 0.00001 0.00019 
4 hsa03050 Proteasome 56 0.00007 0.00003 
5 hsa04540 Gap junction 281 0.00048 0.02811 
6 hsa00860 Porphyrin and chlorophyll metabolism 65 0.00178 0.00127 
7 hsa00460 Cyanoamino acid metabolism 25 0.00437 0.03776 
8 hsa00500 Starch and sucrose metabolism 128 0.005 0.01821 
9 hsa00362 Benzoate degradation via hydroxylation 7 0.00582 0.03093 
10 hsa01032 Glycan structures - degradation 71 0.00785 0.00578 
11 hsa04612 Antigen processing and presentation 210 0.01045 0.19397 
12 hsa00240 Pyrimidine metabolism 182 0.01081 0.1912 
13 hsa04210 Apoptosis 218 0.01127 0.05984 
14 hsa00600 Sphingolipid metabolism 89 0.01363 0.00272 
15 hsa00040 
Pentose and glucuronate 
interconversions 33 0.01494 0.01643 
16 hsa00670 One carbon pool by folate 45 0.01886 0.15329 
17 hsa00511 N-Glycan degradation 26 0.02655 0.01597 
18 hsa00980 
Metabolism of xenobiotics by cytochrome 
P450 125 0.02695 0.00114 
19 hsa01430 Cell Communication 257 0.0271 0.02781 
20 hsa00643 Styrene degradation 7 0.03211 0.17557 
21 hsa00430 Taurine and hypotaurine metabolism 24 0.0335 0.06485 
22 hsa03030 DNA polymerase 48 0.03395 0.04967 
23 hsa00271 Methionine metabolism 31 0.03497 0.1594 
24 hsa00480 Glutathione metabolism 72 0.03771 0.05048 
25 hsa00532 Chondroitin sulfate biosynthesis 38 0.03911 0.0051 
26 hsa04514 Cell adhesion molecules (CAMs) 358 0.03963 0.31504 
27 hsa00620 Pyruvate metabolism 82 0.04311 0.01934 
28 hsa00530 Aminosugars metabolism 54 0.04367 0.17379 
29 hsa00790 Folate biosynthesis 81 0.04544 0.06403 
30 hsa03060 Protein export 22 0.04562 0.06916 
31 hsa00930 Caprolactam degradation 37 0.046 0.02581 
32 hsa04650 Natural killer cell mediated cytotoxicity 319 0.04881 0.41028 
33 hsa00150 Androgen and estrogen metabolism 87 0.0499 0.40821 
34 hsa00230 Purine metabolism 329 0.04991 0.22131 
35 hsa00904 Diterpenoid biosynthesis 7 0.05539 0.13764 
36 hsa00062 Fatty acid elongation in mitochondria 16 0.0633 0.32756 
37 hsa00220 
Urea cycle and metabolism of amino 
groups 50 0.06802 0.08224 
38 hsa00521 Streptomycin biosynthesis 18 0.08982 0.17166 
39 hsa00531 Glycosaminoglycan degradation 45 0.09137 0.12173 
40 hsa00052 Galactose metabolism 59 0.09848 0.35361 
41 hsa00950 Alkaloid biosynthesis I 10 0.11526 0.09158 
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Kegg 
Pathway Pathway description 
Number 
of 
genes 
LS 
permutation 
p-value 
KS 
permutation 
p-value 
42 hsa00940 
Stilbene, coumarine and lignin 
biosynthesis 18 0.11827 0.33383 
43 hsa00920 Sulfur metabolism 31 0.12827 0.06269 
44 hsa04730 Long-term depression 211 0.13289 0.15454 
45 hsa00260 
Glycine, serine and threonine 
metabolism 98 0.13673 0.21129 
46 hsa00640 Propanoate metabolism 78 0.14639 0.00829 
47 hsa00590 Arachidonic acid metabolism 107 0.16531 0.11577 
48 hsa00602 
Glycosphingolipid biosynthesis - neo-
lactoseries 50 0.17407 0.26578 
49 hsa00360 Phenylalanine metabolism 61 0.17846 0.09649 
50 hsa00310 Lysine degradation 114 0.18368 0.20991 
51 hsa00830 Retinol metabolism 6 0.18508 0.13715 
52 hsa00410 beta-Alanine metabolism 52 0.19474 0.0146 
53 hsa00903 Limonene and pinene degradation 76 0.19822 0.04336 
54 hsa00051 Fructose and mannose metabolism 115 0.19901 0.16073 
55 hsa00340 Histidine metabolism 86 0.21398 0.15742 
56 hsa04720 Long-term potentiation 186 0.22095 0.13386 
57 hsa05040 Huntington 94 0.22645 0.09444 
58 hsa00791 Atrazine degradation 11 0.23033 0.51708 
59 hsa04950 Maturity onset diabetes of the young 46 0.2693 0.32074 
60 hsa00450 Selenoamino acid metabolism 76 0.3249 0.28904 
61 hsa04330 Notch signaling pathway 118 0.32723 0.43381 
62 hsa04120 Ubiquitin mediated proteolysis 116 0.33481 0.49485 
63 hsa05130 NA 66 0.38437 0.54156 
64 hsa05131 NA 66 0.38437 0.54156 
65 hsa03022 Basal transcription factors 67 0.45139 0.25404 
66 hsa00363 Bisphenol A degradation 35 0.45805 0.75343 
67 hsa05010 Alzheimer 66 0.4855 0.3627 
68 hsa04020 Calcium signaling pathway 478 0.49788 0.43331 
69 hsa01031 Glycan structures - biosynthesis 2 164 0.52345 0.17911 
70 hsa00910 Nitrogen metabolism 55 0.52558 0.73335 
71 hsa00533 Keratan sulfate biosynthesis 37 0.53564 0.09225 
72 hsa04610 Complement and coagulation cascades 135 0.55709 0.15736 
73 hsa00710 Carbon fixation 58 0.67427 0.53794 
74 hsa04340 Hedgehog signaling pathway 130 0.72643 0.55913 
75 hsa00561 Glycerolipid metabolism 128 0.84407 0.48472 
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APPENDIX C: Microarray post-hybrizdization quality control results 
Appendix C1: Quality Control Plots 
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Appendix C2.a: RNA Degradation Plots 
 
 
 
Appendix C2.b: The data associated with the RNA degradation plot indicating 
significance levels 
 
0.1% FBS 
Control Set3 
0.1% FBS 
Control Set2 
0.1% FBS 1uM 
Nicotine Set3 
0.1% FBS 1uM 
Nicotine Set2 
10% FBS 
Control Set3 
10% FBS 1uM 
Nicotine Set3 
slope  2.17 2.09 3.36 1.87 1.57 2.11 
pvalue  0 0 0 0 1.00E-06 0 
A 
C 
B 
D 
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